RenovoRx, Inc. RNXT shares are trading higher Thursday after the company released interim data on progression-free survival from Phase 3 open label TIGeR-PaC study of RenovoGem for pancreatic cancer.
What To Know: The interim data, featured as a late-breaking oral presentation at the 2023 ESMO World Congress on Gastrointestinal Cancer, demonstrated an eight-month median PFS benefit, 15 versus 7 months, in delaying the progression of cancer for patients receiving treatment with RenovoGem versus standard-of-care.
"Placing patients at the center of everything we do is a critical focus. We are thrilled to announce these pivotal TIGeR-PaC study results supporting RenovoGem's meaningful clinical benefit and impressive safety profile for patients with LAPC," said Shaun Bagai, CEO, RenovoRx.
"We are committed to advancing this therapy as rapidly as possible, with the goal of delivering a treatment that is capable of improving survival outcomes while preserving patient quality of life in pancreatic cancer."
Related Link: Why DraftKings Stock Is Trading Higher Today
RNXT Price Action: Shares of RNXT were up 7.20% at $2.40 at the time of publication, according to Benzinga Pro.
Image by Michal Jarmoluk from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
